Information for Hospitals & Healthcare Professionals
Early effective treatment of any disease can help avert progression to more serious illness, especially for patients at high risk of disease progression and severe illness, with the additional benefit of reducing the burden on healthcare systems. Monoclonal antibodies, or mAbs are available under the Emergency Use Authorization (EUA) for early outpatient treatment in Louisiana at no cost to patients.
The National Institute of Health COVID-19 Treatment Guidelines have developed a figure that conveniently summarizes pharmacologic management of patients with COVID-19 based on disease severity.
What treatments have been approved?
Casirivimab and imdevimab, administered together (EUA issued November 21, 2020, latest update July 30, 2021)
Bamlanivimab and etesevimab, administered together (EUA issued February 9, 2021)
Sotrovimab (EUA issued May 26, 2021)
Tocilizumab (EUA issued June, 24 2021)
Where can my patient receive monoclonal antibody treatment?
Appropriate candidates should be referred to the nearest facility accepting patients for monoclonal antibody treatment.
A call center is also available to answer questions and provide information related to monoclonal antibody therapeutic treatments at 1-877-332-6585 (English Language); 1-877-366-0310 (Spanish Language).
For more information about the limits of authorized use for these monoclonal antibody therapies, including information about viral variants and antiviral resistance, review the following:
- Fact Sheet for Health Care Providers EUA of Casirivimab and Imdevimab
- English | Spanish
- Fact Sheet for Health Care Providers EUA of Bamlanivimab and Etesevimab
- Fact Sheet for Health Care Providers EUA of Sotrovimab
- Fact Sheet for Health Care Providers EUA of Tocilizumab (ZIP)
|Patient Information||mAb Treatment Locations|